Patients with late-stage (stage III–IV) breast cancer with high PKCλ, c-Met, and ALDH1A3 levels showed a poorer prognosis than patients with low PKCλ, c-Met, and ALDH1A3 levels. This evidence concerns the gene MET and breast carcinoma.